Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.

Oligometastatic prostate cancer (OMPC) is a heterogeneous disease state that is imperfectly understood, and its clinical implications are unclear.

To determine the consensus of a Dutch multidisciplinary expert panel on biological aspects, treatment goals, and management of OMPC in daily clinical practice.

The study comprised a modified Delphi method including an explorative survey with various statements and questions, followed by a consensus meeting to discuss and determine the agreement with revised statements and related items. The panel consisted of 34 Dutch representatives from urology, medical and radiation oncology, radiology, nuclear medicine, and basic research.

Agreement was determined with statements (five-point scale). Consensus was defined as ≥75% panel agreement with a statement.

Consensus existed for 56% of statements. The panel agreed that OMPC comprises a limited metastatic spread in the hormone-sensitive setting, in both the synchronous and the metachronous presentation. Limited metastatic spread was believed to involve three to five metastases and a maximum of two organs. Prostate-specific membrane antigen positron emission tomography/computed tomography scan was currently perceived as the most accurate diagnostic imaging modality. Although there was a consensus that targeted treatment of all metastases in OMPC will delay further dissemination of the disease, opinions on specific treatment regimens were divided. Panel outcomes were limited by the lack of scientific evidence on OMPC.

A multidisciplinary panel reached a consensus that OMPC is a specific disease state requiring a tailored treatment approach. OMPC registries and clinical studies should focus on both the biology and the clinical parameters in relation to optimal treatment strategies in synchronous and metachronous OMPC.

A group of Dutch medical specialists agreed that prostate cancer patients having few metastases may benefit from a new therapeutic approach. Clinical studies need to determine which treatment is best for each specific situation.

European urology oncology. 2019 Aug 07 [Epub ahead of print]

Shafak S Aluwini, Niven Mehra, Martijn P Lolkema, Daniela E Oprea-Lager, Derya Yakar, Herman Stoevelaar, Henk van der Poel, Dutch Oligometastatic Prostate Cancer Working Group , Martijn Busstra, Igle-Jan de Jong, Theo de Reijke, Kim de Vries, Stijn Heijmink, Guido Jenster, Sjoerd Klaver, Jeroen Kneppers, Jules Lavalaye, Gisèle Leyten, Luc Moonen, James Nagaraj, Walter Noordzij, Susanne Osanto, Irma Oving, Eva Schaake, Tom Scheenen, Ivo Schoots, Michiel Sedelaar, Diederik Somford, Franchette van den Berkmortel, Tom van der Hulle, Jochem van der Voort van Zyp, Pim van Leeuwen, Jeroen van Moorselaar, Inge van Oort, Wouter Vogel, Hans Westgeest

Department of Radiation Oncology, UMCG, Groningen, The Netherlands., Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, VU University, Amsterdam, The Netherlands., Department of Radiology, UMCG, Groningen, The Netherlands., Centre for Decision Analysis & Support, Ismar Healthcare NV, Lier, Belgium., Department of Urology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe